U.S. Markets close in 2 hrs 49 mins
  • S&P 500

    3,851.19
    +52.28 (+1.38%)
     
  • Dow 30

    31,181.36
    +250.84 (+0.81%)
     
  • Nasdaq

    13,448.12
    +250.95 (+1.90%)
     
  • Russell 2000

    2,158.11
    +6.97 (+0.32%)
     
  • Crude Oil

    53.33
    +0.35 (+0.66%)
     
  • Gold

    1,863.90
    +23.70 (+1.29%)
     
  • Silver

    25.72
    +0.40 (+1.56%)
     
  • EUR/USD

    1.2109
    -0.0024 (-0.1938%)
     
  • 10-Yr Bond

    1.0900
    -0.0020 (-0.18%)
     
  • Vix

    21.74
    -1.50 (-6.45%)
     
  • GBP/USD

    1.3645
    +0.0011 (+0.0791%)
     
  • USD/JPY

    103.6100
    -0.2820 (-0.2714%)
     
  • BTC-USD

    34,867.86
    +467.89 (+1.36%)
     
  • CMC Crypto 200

    689.24
    -11.37 (-1.62%)
     
  • FTSE 100

    6,740.39
    +27.44 (+0.41%)
     
  • Nikkei 225

    28,523.26
    -110.24 (-0.39%)
     

vTv Therapeutics to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event Virtually

vTv Therapeutics Inc.
·3 min read

HIGH POINT, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced that it is participating in the LifeSci Partners 10th Annual Healthcare Corporate Access Event held virtually from January 11-14 2021.

Company management will be conducting one-on-one virtual meetings during the week of the conference concurrently with J.P. Morgan’s 39th Annual Healthcare Conference. To request a meeting, please visit the following registration link http://lifesci.events/LifeSci2021.

About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes and inflammatory disorders. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), renal disease and genetic mitochondrial diseases. For more information, please visit www.vtvtherapeutics.com or follow us on Twitter: @vTvTherapeutics.

Forward-Looking Statements
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.

Contacts

Investors:

Corey Davis
LifeSci Advisors
CDavis@LifeSciAdvisors.com

or

Media:

PR@vtvtherapeutics.com

Source: vTv Therapeutics Inc.